GE HealthCare Technologies (GEHC) Stock

Dublin, January 2, 2025 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included a new report titled "United States External Cardiology Remote Monitors Market Outlook to 2033." This report offers information on the market segments for External Cardiology Remote Monitors, including value in USD, volume in units, and average prices in USD.

Investors focusing on the Medical - Products sector may be familiar with GE HealthCare Technologies (GEHC) and Insulet (PODD). However, which of these companies is the better choice for those seeking undervalued stocks?

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

Since October 2023, GE HealthCare's stock has risen almost 27%, thanks to its AI strategies and innovations in healthcare diagnostics, even with some fluctuations in revenue growth. The positive forecast for 2025 is backed by GEHC's advancements in AI, anticipated increases in sales and profits, and a large backlog of $19.6 billion. Their AI healthcare solutions are expected to improve diagnostic accuracy, lower treatment costs, and boost market growth, positioning GEHC as a leader with many FDA-approved devices.

GEHC's ongoing emphasis on new ideas, buying other companies, and forming partnerships creates a positive outlook for the stock.

GE HealthCare Technologies is considered a good investment because of its strong growth potential, a solid backlog of orders, and a favorable valuation compared to its competitors. The company's revenue is boosted by new product developments, like the FDA-approved Flyrcado, and a possible increase in demand from China. Additionally, margins are likely to improve through cost-saving measures, increased production efficiency, and smart pricing strategies, aiming for an EBIT margin of around 15% to 20% in the medium term.

GE HealthCare has announced that Aurora will broaden the types of CT procedures available, while Clarify DL will improve the quality of SPECT images.

GE HealthCare has announced that it has submitted its CleaRecon DL technology to the FDA, which aims to enhance CBCT images.

GE HealthCare has introduced the new Sonic DL for 3D, which will shorten scan times and deliver quicker, high-quality images for most MR scans.